You are here

FDA Sets Review Date for New COPD Drug, Anoro Ellipta

Approval decision expected in December (Feb. 19)

The FDA has accepted the new drug application (NDA) for an investigational once-daily LAMA/LABA combination medicine — umeclidinium bromide and vilanterol (UMEC/VI, GlaxoSmithKline/Theravance) — for patients with chronic obstructive pulmonary disease (COPD).

The Prescription Drug User Fee Act (PDUFA) goal date is December 18, 2013.

UMEC/VI — with the proposed brand name of Anoro — is a combination of two investigational bronchodilator molecules: umeclidinium bromide (formerly known as GSK573719, a long-acting muscarinic antagonist [LAMA]) and vilanterol (a long-acting beta2 agonist [LABA]). The combo drug is administered using the Ellipta inhaler.

Source: GSK; February 19, 2013.

Recent Headlines

First Devices Cleared for Diagnostic Testing Via Throat, Rectum Specimens
First New Medication for Seizure Clusters in More Than Two Decades
Novel, Low-cost Device Highly Accurate at Screening Newborn Jaundice
Mode Delivers Antivirals Safely, Cheaply to Remote Regions
Risk May Remain for 6 Months After Treatment
FDA Removes Boxed Warning With Drug’s Fifth Approval
Overeager Use of Recommendations Creates Problems
Averts Disease Worsening, Reduces Potential for Blindness
Artificial Intelligence Enables Platform to Detect Amyloid PET Status